In conclusion, we provided evidence that TRPV1 signaling regulates neuroimmune crosstalk in MS, suggesting that its pharmacological modulation could affect MS disease course and inflammatory neurodegeneration. Here, TRPV1 is linked to myeloid sarcoma.